- Home
- LE vs TIL Comparison
LE vs TIL Comparison
Compare LE & TIL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LE
- TIL
- Stock Information
- Founded
- LE 1963
- TIL 2018
- Country
- LE United States
- TIL United States
- Employees
- LE N/A
- TIL N/A
- Industry
- LE Clothing/Shoe/Accessory Stores
- TIL Biotechnology: Pharmaceutical Preparations
- Sector
- LE Consumer Discretionary
- TIL Health Care
- Exchange
- LE Nasdaq
- TIL Nasdaq
- Market Cap
- LE 280.4M
- TIL 230.1M
- IPO Year
- LE N/A
- TIL 2021
- Fundamental
- Price
- LE $9.32
- TIL $27.56
- Analyst Decision
- LE Strong Buy
- TIL Buy
- Analyst Count
- LE 1
- TIL 5
- Target Price
- LE $20.00
- TIL $119.00
- AVG Volume (30 Days)
- LE 633.2K
- TIL 503.4K
- Earning Date
- LE 06-05-2025
- TIL 08-12-2025
- Dividend Yield
- LE N/A
- TIL N/A
- EPS Growth
- LE N/A
- TIL N/A
- EPS
- LE 0.14
- TIL N/A
- Revenue
- LE $1,338,672,000.00
- TIL N/A
- Revenue This Year
- LE $3.31
- TIL N/A
- Revenue Next Year
- LE $2.34
- TIL N/A
- P/E Ratio
- LE $67.51
- TIL N/A
- Revenue Growth
- LE N/A
- TIL N/A
- 52 Week Low
- LE $7.65
- TIL $9.62
- 52 Week High
- LE $19.88
- TIL $92.00
- Technical
- Relative Strength Index (RSI)
- LE 54.05
- TIL 51.84
- Support Level
- LE $8.50
- TIL $27.01
- Resistance Level
- LE $9.76
- TIL $42.79
- Average True Range (ATR)
- LE 0.83
- TIL 5.01
- MACD
- LE 0.08
- TIL -1.00
- Stochastic Oscillator
- LE 79.15
- TIL 9.82
About LE Lands' End Inc.
Lands' End Inc is a United States-based multi-channel retailer of casual clothing, accessories, and footwear, as well as home products. The company's operating segment includes U.S. eCommerce; International; Outfitters; Third Party and Retail. It generates maximum revenue from the U.S. eCommerce segment. The U.S. eCommerce segment offers products through the company's eCommerce website. Geographically operates in USA, Europe, Asia, it derives a majority of its revenue from the United States.
About TIL Instil Bio Inc.
Instil Bio Inc is a clinical-stage biopharmaceutical company focused on developing a cell therapy pipeline of autologous tumor infiltrating lymphocyte, or TIL, therapies for the treatment of patients with cancer. It is also engaged in developing a novel class of genetically engineered TIL therapies using its Co-Stimulatory Antigen Receptor, or CoStAR, platform. Its pipeline includes ITIL-306 which expresses a CoStAR molecule designed to recognize, a tumor-associated antigen that is expressed on numerous solid tumors, including ovarian cancer, uterine cancer, NSCLC, and renal cancer.